150+ LANGUAGES · ISO 17100 CERTIFIED · SAME-DAY TURNAROUND
Pharmaceutical Translation Services
ISO 17100 certified pharmaceutical translation services for clinical trials, labeling translation and patient information leaflets — linguist-led, from £30 per page.
- 150+ Languages
- ISO 17100 Certified
- Same-day Turnaround
Get a free, no-obligation quote
What we do
Our services
What is pharmaceutical translation?
Pharmaceutical translation is the specialist translation of regulated drug, clinical trial, and labelling documentation between languages under ISO 17100 controls, performed by qualified linguists with a deep understanding of medical terminology so pharmaceutical companies stay compliant with EMA, MHRA and FDA rules.
How does pharmaceutical translation differ from general medical translation?
Pharmaceutical translation differs from general medical translation by scope and legal weight: medical translation covers patient records and clinician communication, while pharmaceutical translation covers regulated drug submissions, clinical trial protocols and labeling translation, where a single mistranslated dosage carries EMA or FDA rejection risk.
What types of documents require pharmaceutical translation?
Pharmaceutical documents that require translation include clinical trial protocols, informed consent forms, patient information leaflets, IFUs, SmPCs, drug labels, CTD dossier modules, pharmacovigilance CIOMS reports and marketing authorisation applications submitted to the EMA, MHRA or FDA.
Why is accurate pharmaceutical translation important?
Accurate pharmaceutical translation is important because a single mistranslated dose, contraindication or excipient can compromise patient safety, trigger EMA or FDA rejection, delay global market access and expose the sponsor to product liability across every target market.
What are the main challenges in pharmaceutical translation?
The main challenges in pharmaceutical translation are dense medical terminology, evolving regulatory requirements in each target market, tight submission deadlines, multilingual QRD compliance, cultural nuances in patient information, and the confidentiality demands of unblinded clinical trial data.
What are the regulatory compliance standards for pharmaceutical translations?
Regulatory compliance standards for pharmaceutical translations include ISO 17100 for the translation process, EMA QRD templates for labelling in Europe, FDA 21 CFR requirements in the United States, MHRA rules in the UK, and ICH E6(R2) GCP for clinical trial documentation.
What we do
What is pharmaceutical translation?
Pharmaceutical translation is the specialist translation of regulated drug, clinical trial, and labelling documentation between languages under ISO 17100 controls, performed by qualified linguists with a deep understanding of medical terminology so pharmaceutical companies stay compliant with EMA, MHRA and FDA rules.
How it works
How does pharmaceutical translation differ from general medical translation?
Pharmaceutical translation differs from general medical translation by scope and legal weight: medical translation covers patient records and clinician communication, while pharmaceutical translation covers regulated drug submissions, clinical trial protocols and labeling translation, where a single mistranslated dosage carries EMA or FDA rejection risk.
What’s included
What is the pharmaceutical translation process at our agency?
Our pharmaceutical translation process runs a five-stage ISO 17100 workflow: scoping and NDA, terminology setup inside our translation management system, translation by a specialist linguist, independent editing, and proofreading, before certified delivery to the pharmaceutical company or CRO.
Complete guide
Everything you need to know
ISO 17100 certified pharmaceutical translation services delivered from London and across the United Kingdom support pharmaceutical companies, CROs and life sciences organisations submitting to the EMA, MHRA and FDA — priced from £30 per page in GBP.
What types of documents require pharmaceutical translation?
Pharmaceutical documents requiring translation span the entire product lifecycle, from first-in-human trial filing through to post-approval variations and pharmacovigilance reporting. Core document types include clinical trial protocols, informed consent forms, patient information leaflets, instructions for use, summaries of product characteristics, drug labels, CTD dossier modules, pharmacovigilance CIOMS forms and marketing authorisation applications submitted to the EMA, MHRA or FDA. Certificates of analysis and quality dossier sections also form part of submissions and post-approval change packages. Each document type carries its own regulatory acceptance rule, template requirement or linguistic validation standard, making specialist pharmaceutical translation essential at every stage.
| Document type | Primary regulator | Acceptance rule |
|---|---|---|
| Patient Information Leaflet (PIL) | EMA / MHRA | Must match QRD template wording in each target market language |
| Summary of Product Characteristics (SmPC) | EMA / MHRA | QRD-compliant multilingual labelling required |
| Instructions for Use (IFUs) | EMA / FDA | Regulator-aligned target market language; readability validated |
| Informed Consent Form (ICF) | EMA / FDA / IRB | Linguistic validation with conceptual equivalence confirmed |
| CTD dossier modules | EMA / MHRA / FDA | Module 1 region-specific; Modules 2–5 shared across regions |
| CIOMS pharmacovigilance forms | EMA / FDA | Standardised English submission with source translations |
| Clinical study reports | EMA / FDA | ICH E6(R2) GCP-aligned wording and traceability |
| Certificates of analysis | EMA / MHRA / FDA | Accurate terminology for quality and purity data |
Which clinical trial documents need certified translation?
Clinical trial documents requiring certified translation include clinical trial protocols, informed consent forms, investigator brochures, case report forms and patient diaries, each carrying distinct regulatory requirements set by the EMA in Europe and the FDA in the United States. Protocols define the scientific methodology and eligibility criteria; any mistranslation invalidates the statistical framework. Informed consent forms undergo a rigorous linguistic validation process — forward translation, reconciliation, back-translation and cognitive debriefing review — to confirm conceptual equivalence between the source and target language versions. Investigator brochures summarise preclinical and clinical safety data and must read unambiguously to site investigators across every participating country. Patient diaries are patient-facing and must be adapted to the reading level of the intended population without altering the regulated content. See Certified Translation Services for evidence accepted by regulators.
What labelling translation and packaging content is in scope?
Labelling translation covers drug packaging, patient information leaflets, instructions for use, blister foil text, carton artwork and summaries of product characteristics, all translated so that wording matches the QRD template and the target market language requirements set by the EMA or MHRA. The PIL must match QRD template wording in the target market language; this is a mandatory acceptance condition, not a best-practice recommendation. Every artwork element is version-controlled to ensure that print files reflect only approved translation states. Drug names are verified against International Nonproprietary Names lists to eliminate look-alike or sound-alike errors that could reach dispensing pharmacists or patients.
Which regulatory submissions rely on accurate pharmaceutical translations?
Regulatory submissions that depend on accurate pharmaceutical translations include CTD modules, marketing authorisation applications, variations, renewals, pharmacovigilance PSURs and responses to EMA or FDA questions, each demanding traceable version control across the full dossier lifecycle. Regulators request documented evidence of how translation versions were controlled during the review cycle, and inspectors may audit the translation management system records directly. Our workflow assigns a unique version identifier to every translated file, logs the name of each linguist who performed translation, editing and proofreading, and retains the full audit trail for the duration required by sponsor SOPs.
Pricing
Why is accurate pharmaceutical translation important?
Accurate pharmaceutical translation is important because a single mistranslated dose, contraindication or excipient can compromise patient safety, trigger EMA or FDA rejection, delay global market access and expose the sponsor to product liability across every target market. The consequences of translation error in this sector are not limited to commercial delay — ambiguity in dosage instructions has directly contributed to adverse drug events in clinical practice. Regulatory bodies including the EMA, MHRA and FDA treat translation quality as part of the submission dossier itself; a poorly translated clinical trial protocol or patient information leaflet is grounds for refusal of a marketing authorisation application. Pharmaceutical translation therefore carries both a safety mandate and a commercial imperative that general translation work does not.
Compliance with ISO 17100 translation services standards is the baseline that regulators and auditors expect, precisely because it enforces the separation of roles — translator, editor and proofreader — that reduces the probability of undetected error. A TEP workflow inside a compliant translation management system further protects accuracy by applying controlled terminology consistently across every version of a document, preventing drift between dossier updates. With language coverage extending to 150+ languages for multinational submissions, maintaining that consistency at scale is as important as achieving it in a single language pair.
How does translation accuracy affect patient safety and regulatory outcomes?
Translation accuracy affects patient safety and regulatory outcomes directly and simultaneously: mislabelled dosage instructions cause adverse events, while ambiguous or non-equivalent informed consent forms invalidate trial data and force EMA or FDA resubmission. Patients enrolled in clinical trials in non-English-speaking countries rely entirely on translated protocols and consent documents to understand what they are agreeing to; a conceptual error in that translation removes their ability to give genuinely informed consent. Accurate pharmaceutical translation protects enrolled patients, preserves the integrity of trial data and safeguards the sponsor’s regulatory timeline — all three outcomes depend on the same underlying quality of the translated text. That link between patient safety and regulatory outcome is the reason pharmaceutical translation is treated as a regulated activity, not a commodity service.
What are the main challenges in pharmaceutical translation?
The main challenges in pharmaceutical translation are dense and evolving medical terminology, divergent regulatory requirements across the EMA, MHRA and FDA, compressed submission deadlines, multilingual QRD compliance across up to 24 EU official languages, cultural and readability adaptation of patient-facing materials, and the confidentiality demands of unblinded clinical trial data. Each challenge requires a distinct control, and the controls must work in concert across a project team that may span multiple linguists working in parallel on a large dossier.
- Terminology drift: the same drug concept expressed inconsistently across dossier sections creates ambiguity for regulators; controlled by a project-specific termbase maintained inside the translation management system throughout the product lifecycle.
- Regulatory variability: the EMA sets QRD template requirements for EU labelling, the FDA requires English-language dossiers with certified translations of foreign-language evidence, and the MHRA applies its own post-Brexit rules for UK marketing authorisations — each demands different content controls.
- Short deadlines: post-approval labelling updates and responses to regulator questions often carry fixed submission windows; the standard throughput benchmark of 1,500–2,000 words per linguist per day structures project planning, with same-day rush available for volumes up to 10,000 words at a 25–50% surcharge.
- Readability constraints: patient information leaflets must meet QRD template wording requirements while remaining comprehensible to lay readers at the mandated reading level.
- Data protection: unblinded clinical trial data is among the most commercially sensitive content in the life sciences sector; GDPR-aligned handling, encrypted transfer and role-based access are non-negotiable.
- Version control: dossier submissions are living documents; every update must be traceable, and the translation management system must prevent superseded versions from re-entering the workflow.
How do we handle medical terminology and cultural nuances?
We handle medical terminology and cultural nuances by pairing subject-matter linguists with a controlled, project-specific termbase inside a compliant translation management system, adapting patient-facing wording to local reading levels without altering regulated content or QRD template requirements. Dedicated glossaries are built at project inception, reviewed by the editing linguist at every project stage, and updated as the product lifecycle evolves. Consistency in terminology is treated as a safety issue rather than a stylistic preference: regulators and healthcare professionals expect identical terminology across all sections of a submission, and any deviation attracts questions during review.
How do we protect confidentiality on clinical trial documentation?
We protect confidentiality on clinical trial documentation through signed NDAs at project intake, secure encrypted file transfer, role-based access controls inside the translation management system, and GDPR-aligned data retention periods, so sponsors and CROs can share unblinded trial data with our translation team without risk of unauthorised disclosure. No file leaves the audited project environment. Retention periods are aligned with sponsor SOPs and, where applicable, with the requirements of the applicable clinical trial regulation. Linguists working on sensitive protocols are individually named in the project record, creating a clear chain of custody from intake to certified delivery.
What are the regulatory compliance standards for pharmaceutical translations?
Regulatory compliance standards for pharmaceutical translations form a layered framework covering process, content and jurisdiction. At the process level, ISO 17100 is the governing standard for translation services, mandating a TEP workflow with documented linguist qualifications, project records and continuous professional development. At the content level, the EMA sets QRD template requirements and multilingual labelling rules for European submissions, the FDA applies 21 CFR Parts 201, 312 and 11 in the United States, and the MHRA oversees post-Brexit marketing authorisations and pharmacovigilance in the UK. Clinical trial documentation is additionally governed by ICH E6(R2) GCP across all three jurisdictions, and multi-regional dossier structure follows ICH M4 CTD format. EU Regulation 536/2014 on clinical trials adds further obligations for sponsors operating across EU member states.
How does ISO 17100 govern our translation process?
ISO 17100 governs our translation process by mandating a full TEP workflow — translation, editing and proofreading carried out by separate, qualified linguists — together with documented linguist qualifications, continuous professional development and auditable project records. The standard defines minimum competence requirements for each role in the workflow, preventing a single linguist from both translating and self-reviewing safety-critical content. It requires that translation memories and termbases are maintained within a compliant translation management system, so terminology decisions are applied consistently across every update to a living dossier. ISO 17100 is the recognised benchmark for translation services quality and is the standard that regulatory auditors expect a pharmaceutical translation partner to hold. Our medical translators hold relevant professional registrations and their qualifications are recorded in the project file for every assignment.
How do EMA and FDA requirements shape pharmaceutical translation?
EMA and FDA requirements shape pharmaceutical translation by dictating template wording, submission language pairs, content traceability and, in some cases, the specific format of translated evidence. The EMA sets QRD template requirements and multilingual labelling rules, meaning that every patient information leaflet and summary of product characteristics submitted for a European marketing authorisation must match QRD template wording in the target market language — a mandatory acceptance condition across all EU official languages. National competent authorities perform the linguistic review of EMA submissions across a standard 25-day assessment cycle, making translation quality a direct factor in timeline predictability. The FDA requires English-language dossiers and mandates certified translations of any foreign-language source evidence submitted in support of an IND or NDA, with a signed statement of accuracy from the translator accompanying each document. The MHRA applies its own distinct rules for UK submissions following the end of the Brexit transition period, requiring sponsors to treat the UK as a separate regulatory territory with its own pharmacovigilance and labelling obligations.
How it works
What should you consider when choosing a pharmaceutical translation service?
When choosing a pharmaceutical translation service, the decision criteria go well beyond price per word. The partner must hold ISO 17100 certification as the baseline process standard, employ linguists with verifiable life sciences credentials in the relevant therapeutic area, and demonstrate documented experience with EMA, MHRA and FDA submissions. A compliant translation management system with translation memory and controlled termbase is essential for maintaining consistency across recurring dossier updates. Secure data handling — including NDA, encrypted file transfer and GDPR-aligned retention — is non-negotiable when sharing unblinded clinical trial content. Published GBP pricing with no hidden surcharges gives sponsors and CROs the cost predictability needed for trial budgeting. A UK-based translation partner is additionally accountable under English law, providing a clear contractual framework for regulated work.
- ISO 17100 certification: confirms the TEP workflow, linguist qualification requirements and audit trail are in place — the standard regulators expect of a pharmaceutical translation partner.
- Linguist profile: native-language translator with a pharmacology, clinical research or regulatory affairs background, not a generalist with a medical dictionary.
- Regulatory track record: documented experience across EMA, MHRA and FDA submissions in the relevant document categories — labelling, clinical trial protocols, CTD modules.
- Language coverage: capacity across 150+ languages for multinational trials and multi-regional marketing authorisation applications.
- Technology: compliant translation management system with translation memory, termbase and version control — not a general-purpose file-sharing platform.
- Data controls: NDA at intake, encrypted transfer, role-based access inside the TMS, GDPR-aligned retention periods matched to sponsor SOPs.
- Turnaround capacity: ability to plan against the 1,500–2,000 words per linguist per day benchmark and to mobilise parallel linguists for same-day rush requirements.
- Pricing transparency: published GBP rates from £30 per page, clear surcharge structure for rush work, no hidden conversion or project-management fees.
Which credentials should a pharmaceutical translation partner hold?
A pharmaceutical translation partner should hold ISO 17100 certification as the governing process standard, alongside evidence of linguists holding relevant professional registrations and sector-specific qualifications in life sciences, clinical research or regulatory affairs. The partner should be able to demonstrate continuous professional development records for its medical translators, show documented experience across clinical trial and labelling translation for the specific regulatory jurisdictions in scope, and provide named-linguist project records for every completed assignment. Every project record must tie a named translator, editor and proofreader to the delivered file, creating the traceability chain that regulatory inspectors expect when they review a sponsor’s translation controls during a GCP or GMP audit.
How do accuracy and speed balance in a pharmaceutical translation service?
Accuracy and speed balance in a pharmaceutical translation service through a TEP workflow supported by translation memory and controlled terminology management, so specialist linguists can apply and reuse validated, regulator-reviewed wording without compromising compliance on each new dossier update. Translation memory cuts turnaround time on repeat submissions — a dossier variation that reuses 60% of an existing SmPC is translated substantially faster than a first-time project, while the termbase ensures that reused segments carry the same approved terminology. Machine translation post-editing, where applied to appropriate content, remains under mandatory human expert review for every safety-critical section. The result is a service that delivers to the 1,500–2,000 words per linguist per day benchmark on standard projects and to same-day schedules on rush work, without reducing the quality controls that EMA, MHRA and FDA submissions demand.
Which languages and markets does our pharmaceutical translation service cover?
Our pharmaceutical translation service covers 150+ languages across the EU, UK, US, LATAM, MENA and APAC pharmaceutical sector, giving global pharmaceutical clients single-vendor language solutions for EMA multilingual labelling, FDA submissions and global market access. Our global footprint supports global healthcare programmes without switching vendors between regions.
- EU 24 official languages for QRD-compliant PILs and SmPCs.
- English (US and UK) for FDA and MHRA dossiers.
- Simplified and Traditional Chinese, Japanese, Korean for APAC submissions.
- Arabic, Hebrew, Turkish for MENA markets.
- Spanish (LATAM variants), Brazilian Portuguese for LATAM authorities.
How do we answer common pharmaceutical translation questions?
Common pharmaceutical translation questions concern job pay, translation types, free medical translation apps and pharmaceutical meaning: the answers below clarify how professional specialist translation services differ from consumer tools.
What is the highest paid translating job?
The highest paid translating job is typically specialised pharmaceutical, patent or legal translation for regulated industries, where medical translators with life sciences qualifications and EMA or FDA submission experience command the top rates. Rarity of qualified linguists drives the premium.
What are the four types of translations?
The four types of translations most relevant to the medical industry are certified translation, Technical Translation Services, Legal Translation Services and specialist translation services such as pharmaceutical translation, each governed by different accuracy and compliance rules.
- Certified translation — signed statement of accuracy for official use.
- Technical translation — engineering, IFUs and product documentation.
- Legal translation — contracts, licensing, product liability files.
- Specialist translation — pharmaceutical, patent and regulatory content.
Is there a free medical translation app?
Free medical translation apps such as Google Translate exist for casual patient information, but they lack ISO 17100 controls, medical terminology validation and confidentiality safeguards, so they are unsuitable for regulated pharmaceutical documents or clinical documentation. Consumer AI tools cannot sign an NDA or produce an audit trail.
What does “pharmaceutical” mean in translation contexts?
In translation contexts, “pharmaceutical” means content relating to the research, manufacture, regulation and use of medications, spanning clinical trial protocols, drug labelling, patient information leaflets and pharmacovigilance reports produced by the pharmaceutical industry.
How do you request a pharmaceutical translation quote?
Request a pharmaceutical translation quote by sending source files and target languages to our London team: we return an ISO 17100 scoped quote in GBP within one working hour, with confirmed turnaround and a signed NDA before any pharmaceutical documents leave your environment.
- Send source files, target languages and deadline to our London office.
- Sign the NDA we return with the scoped quote.
- Approve the GBP quote, turnaround and named linguist team.
- Receive certified files, statement of accuracy and version log.
Start your project through Request a Translation Quote and a project manager will confirm scope, price and delivery within one working hour.